DynaGen Inc. said it has signed an agreement with The RoyalTropical Institute of Amsterdam, the Netherlands, for rights toantibodies to be used in the development of tests to diagnosetuberculosis and other mycobacterial diseases.
The Cambridge, Mass., company said the license will expand itsportfolio of diagnostic tests for mycobacterial diseases.DynaGen noted that TB has been resurging in the United Statesas a consequence of AIDS.
DynaGen shares (NASDAQ:DYGN) closed up 50 cents at $6.88 onFriday.
(c) 1997 American Health Consultants. All rights reserved.